Beijing, March 25, 2024/Mainest/ -- Beijing Tongrentang Technology Development Co., Ltd. (”Tung Yan Tong Technology”or”The Group”, 1666.HK) is pleased to announce the Group's audited consolidated results for the year ended 31 December 2013.

In 2013, the Group achieved revenues of RMB67.7 billion, an increase of 13.04% year-on-year; achieved net net income of RMB5.9 billion, an increase of 1.25% year-on-year; in terms of products, the Group sold 62 products of more than RMB 500 million and sales of more than RMB 1 billion. At the same time, the Group had a cash and equivalents balance of RMB27.5 billion; receivables and notes receivable decreased significantly by RMB6.1 billion compared to the same period last year, down 40.67% year-on-year, maintaining good financial condition.

The Board considers that the main reasons for the Group's steady business growth in fiscal 2023 include:

Macro level: balanced coordination of development of Chinese and Western medicine and general base+the potential of large health needs is huge;

At the Group level: adapt to the new normal in the Chinese pharmaceutical industry, continuously focus on core competitive advantages and build a diversified marketing development model;

Operational level: Maintain financial health during the year with the risks and challenges posed by multiple stresses such as economic downturns and rising raw material prices.

In 2014, the Group will focus on improving its variety management capabilities, channel expansion capabilities, marketing services capabilities, delving into development potential, and actively cultivating new growth points to ensure that the objectives of the “Fourteen Five” plan are fulfilled and continue to promote the high-quality development of the Group.

Forward-Looking Statements

THIS ANNOUNCEMENT CONTAINS CERTAIN FORWARD-LOOKING STATEMENTS OR USES CERTAIN FORWARD-LOOKING TERMS, SUCH STATEMENTS OR TERMS ARE BASED ON THE EXPECTATIONS, ESTIMATES AND ASSUMPTIONS CURRENTLY HELD BY TANG YIN TANG TECHNOLOGY REGARDING THE OPERATIONS AND MARKETS OF THE GROUP AND REFLECT THE VIEWS OF TANG YIN TANG TECHNOLOGY AS OF THE DATE OF THE ANNOUNCEMENT. Such forward-looking statements are not guarantees of the Group's future performance and are subject to market risks, uncertainties and factors beyond the control of the I&T industry. Therefore, actual results and assumptions and statements made in this announcement differ materially. Shareholders and potential investors of the Group are advised not to rely on forward-looking statements and to exercise caution when buying and selling the Group's securities.

About Tong Yan Tong Technology

“Tong Rentang” is an old name for the Chinese medicine industry. It was founded in 1669 and has a history of more than 350 years. Tung Yan Tong Technology is a product supply unit established in March 2000, based on modern pharmaceutical technology, under the ownership of “Tung Shuren de, Jisei Health”, which is based on modern pharmaceutical technology, with the role of “Tung Shuren de, Jisei Health”, and adheres to “unique formula, multifaceted ingredients, exquisite craftsmanship and impressive effect” High-tech modern Chinese medicine enterprise with medicinal characteristics.

Tung Yan Tong Technology was listed on the HKEX Startup Board in October 2003 and transferred to the HKEX Main Board in July 2010. The product consists of more than 20 dosage forms including pills, tablets, granules, and more. These include more than 100 varieties of hexagudine yellow pills, agave pills, ankyl tablets, intravenous oral solution, cold cleansing granules and more.